342 related articles for article (PubMed ID: 16219797)
1. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Eichhorst BF; Busch R; Hopfinger G; Pasold R; Hensel M; Steinbrecher C; Siehl S; Jäger U; Bergmann M; Stilgenbauer S; Schweighofer C; Wendtner CM; Döhner H; Brittinger G; Emmerich B; Hallek M;
Blood; 2006 Feb; 107(3):885-91. PubMed ID: 16219797
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
3. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
4. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
Eichhorst BF; Busch R; Obwandner T; Kuhn-Hallek I; Herschbach P; Hallek M;
J Clin Oncol; 2007 May; 25(13):1722-31. PubMed ID: 17389338
[TBL] [Abstract][Full Text] [Related]
6. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
[TBL] [Abstract][Full Text] [Related]
7. CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.
Johnson GG; Lin K; Cox TF; Oates M; Sibson DR; Eccles R; Lloyd B; Gardiner LJ; Carr DF; Pirmohamed M; Strefford JC; Oscier DG; Gonzalez de Castro D; Else M; Catovsky D; Pettitt AR
Blood; 2013 Dec; 122(26):4253-8. PubMed ID: 24128861
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
9. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
Eichhorst BF; Busch R; Schweighofer C; Wendtner CM; Emmerich B; Hallek M;
Br J Haematol; 2007 Jan; 136(1):63-72. PubMed ID: 17083342
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
Hallek M; Schmitt B; Wilhelm M; Busch R; Kröber A; Fostitsch HP; Sezer O; Herold M; Knauf W; Wendtner CM; Kuse R; Freund M; Franke A; Schriever F; Nerl C; Döhner H; Thiel E; Hiddemann W; Brittinger G; Emmerich B;
Br J Haematol; 2001 Aug; 114(2):342-8. PubMed ID: 11529853
[TBL] [Abstract][Full Text] [Related]
11. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
Weiss MA; Glenn M; Maslak P; Rahman Z; Noy A; Zelenetz A; Scheinberg DA; Golde DW
Leukemia; 2000 Sep; 14(9):1577-82. PubMed ID: 10995003
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
14. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
16. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
17. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Cortes J; Beran M; Koller CA; Giles FJ; Lerner S; Keating M
J Clin Oncol; 2001 Mar; 19(5):1414-20. PubMed ID: 11230486
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.
Schiavone EM; De Simone M; Palmieri S; Annunziata M; Pocali B; Copia C; D'Amico MR; Vecchio LD; Ferrara F
Eur J Haematol; 2003 Jul; 71(1):23-8. PubMed ID: 12801295
[TBL] [Abstract][Full Text] [Related]
19. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Geisler CH; van T' Veer MB; Jurlander J; Walewski J; Tjønnfjord G; Itälä Remes M; Kimby E; Kozak T; Polliack A; Wu KL; Wittebol S; Abrahamse-Testroote MC; Doorduijn J; Ghidey Alemayehu W; van Oers MH
Blood; 2014 May; 123(21):3255-62. PubMed ID: 24735962
[TBL] [Abstract][Full Text] [Related]
20. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Catovsky D; Richards S; Matutes E; Oscier D; Dyer M; Bezares RF; Pettitt AR; Hamblin T; Milligan DW; Child JA; Hamilton MS; Dearden CE; Smith AG; Bosanquet AG; Davis Z; Brito-Babapulle V; Else M; Wade R; Hillmen P; ;
Lancet; 2007 Jul; 370(9583):230-239. PubMed ID: 17658394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]